Business Wire

SES Selects Two U.S. Companies to Build Four New Satellites as Part of Accelerated C-Band Clearing Plan

Share

SES, the leader in global content connectivity solutions, announces it has selected two U.S. satellite manufacturers, Northrop Grumman and the Boeing Company, to deliver four new satellites as part of the company’s accelerated C-band clearing plan to meet the Federal Communications Commission’s objectives to roll-out 5G services.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200616005487/en/

Boeing/Artist’s Rendition of SES-20 and SES-21 satellites (Photo: Business Wire)

Boeing/Artist’s Rendition of SES-20 and SES-21 satellites (Photo: Business Wire)

Northrop Grumman will deliver two flight-proven GeoStar-3 satellites, each equipped with a high-quality C-band payload to deliver the superior customer experience that end users are accustomed to. The two satellites – SES-18 and SES-19 – will be designed, assembled and tested in Dulles, Virginia.

The Boeing Company will deliver a pair of highly efficient all-electric 702SP satellites. The two satellites – SES-20 and SES-21 – will be manufactured and assembled in Los Angeles, California.

These four C-band only new satellites will enable SES to clear 280 MHz of mid-band spectrum for 5G use while seamlessly migrating SES’s existing C-band customers. Each satellite will have 10 primary transponders of 36 MHz plus back-up tubes so they can enable the broadcast delivery of digital television to more than 120 million TV homes as well as provide critical data services. The satellites, when launched in Q3 2022, will be positioned at 103 degrees West, 131 degrees West and 135 degrees West orbital slots. The cost of manufacturing these four satellites is part of the USD 1.6 billion investment envelope that SES has announced in May.

SES is committed to investing in America by procuring services and equipment needed for the C-band transition from large and small businesses across the U.S., and these significant partnerships with Northrop Grumman and the Boeing Company are cornerstones of that commitment.

“Given the FCC’s strong leadership in providing for accelerated clearing of precious C-band spectrum in the U.S., our focus is on delivering on our commitment and making the spectrum available in the shortest possible time while ensuring that we protect the broadcast customers and communities that we have built over 35 years,” said Steve Collar, CEO at SES. “To meet our deadlines to clear C-band spectrum, we have selected established American satellite manufacturers in Northrop Grumman and Boeing with their focus on heritage, reliability and minimal risk to build these four satellites, enabling us to fully support the FCC’s 5G Fast initiative.”

Follow us on:

Social Media
Blog
Media Library

About SES

SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries over 8,300 channels and has an unparalleled reach of 367 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com.

Contact information

For further information please contact:

Suzanne Ong
External Communications
Tel. +352 710 725 500
suzanne.ong@ses.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

HCL Technologies Announces Intent to Acquire Leading Australian IT Solutions Company, DWS Limited21.9.2020 04:47:00 EESTPress release

HCL Technologies, (HCL), a leading global technology company, today announced its intent to acquire DWS Limited (ASX: DWS), a leading Australian IT, business and management consulting group. As the IT industry continues to evolve and the growing demand for digital strategies increases, DWS, with over 700 employees and offices in Melbourne, Sydney, Adelaide, Brisbane, and Canberra, delivers business and technology innovation to large clients across a spectrum of verticals. The DWS Group, with FY20 revenue at A$ 167.9 million, provides a wide range of IT services including Digital Transformation, Application development & support, Program & Project Management and Consulting. The acquisition of DWS will strongly enhance HCL’s contribution to Digital initiatives in Australia and New Zealand while strengthening HCL’s client portfolio across key industries. “We are excited for this expansion of HCL Technologies in Australia and New Zealand and are confident that our combined strengths will f

Janssen Presents Findings from Global, Multi-Centre Trial Examining Amivantamab in Combination with Lazertinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer21.9.2020 02:01:00 EESTPress release

FOR EU TRADE AND MEDICAL MEDIA ONLY. NOT FOR DISTRIBUTION IN BENELUX. The Janssen Pharmaceutical Companies of Johnson & Johnson announced yesterday interim results from the CHRYSALIS study (NCT02609776) evaluating amivantamab, a fully human bispecific antibody that targets epidermal growth factor receptor (EGFR) and mesenchymal epithelial transition factor (MET) mutations,1 in combination with the third-generation EGFR tyrosine kinase inhibitor (TKI) lazertinib2 in patients with non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or L858R mutations.3 Investigators assessed efficacy using overall response rate (ORR) per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1), clinical benefit rate, duration of response and the safety profile of amivantamab and lazertinib, in the 91 patients treated with the combination across dose escalation and expansion cohorts.3 The study results were presented at the European Society for Medical Oncology (ESMO) Virtual Con

ESMO 2020: Cabometyx® (cabozantinib) in Combination With Opdivo® (nivolumab) Demonstrates Significant Survival Benefits in Patients With Advanced Renal Cell Carcinoma in Pivotal Phase III CheckMate -9ER Trial19.9.2020 19:30:00 EESTPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the first presentation of results from the pivotal Phase III CheckMate -9ER trial, in which Cabometyx® (cabozantinib) in combination with Bristol Myers Squibb’s Opdivo® (nivolumab) demonstrated significant improvements across all efficacy endpoints, including overall survival (OS), in previously untreated advanced renal cell carcinoma (RCC).1 Cabometyx® in combination with Opdivo® reduced the risk of death by 40% versus sunitinib (HR: 0.60 [98.89% Confidence Interval [CI]: 0.40–0.89]; p= 0.0010; median OS not reached in either arm). In patients receiving Cabometyx® in combination with Opdivo®, median progression-free survival (PFS), the trial’s primary endpoint, was doubled compared to those receiving sunitinib alone: 16.6 months versus 8.3 months respectively (Hazard Ratio [HR]: 0.51 [95% CI 0.41–0.64], p < 0.0001). In addition, Cabometyx® in combination with Opdivo® demonstrated a superior objective response rate, wit

Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress18.9.2020 13:55:00 EESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the company is presenting data from its lung cancer portfolio at the virtual European Society for Medical Oncology (ESMO) conference. Notably, insights from sub-analyses of the Phase 3 ALTA 1L study reinforce both the compelling evidence of intracranial efficacy with ALUNBRIG® (brigatinib) as a first-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) as well as associated quality of life (QoL) data. Takeda is also featuring updated 10-month follow-up results from the Phase 1/2 trial of mobocertinib (TAK-788), demonstrating mobocertinib achieved a duration of response (DoR) of more than one year in the trial’s study population of patients with epidermal growth factor receptor (EGFR) Exon20 insertion+ metastatic NSCLC (mNSCLC). “We’re pleased to present our ongoing research in lung cancer at this year’s virtual ESMO congress, including new

Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal18.9.2020 13:00:00 EESTPress release

Incyte (Nasdaq:INCY) today announced results from its Phase 2 POD1UM-202 trial evaluating retifanlimab, a PD-1 inhibitor, in previously treated patients with advanced squamous cell carcinoma of the anal canal (SCAC) who have progressed following standard platinum-based chemotherapy. The trial enrolled 94 patients, including those with well-controlled human immunodeficiency virus (HIV) infection (10%). Retifanlimab monotherapy resulted in a confirmed objective response rate (ORR) of 14% as determined by independent central review (ICR) using RECIST v1.1. Responses were observed regardless of PD-L1 status, presence of liver metastases, age or HIV+ status. Retifanlimab was generally well-tolerated with a safety profile as expected of a PD-1 inhibitor and no loss of HIV infection control. Key findings from POD1UM-202: N=94 ORR* (95% CI) 13.8% (7.6-22.5) Best OR*, n 1 CR 12 PR 33 SD DCR 48.9% DOR, median (95% CI), months 9.5 (5.6-NE) PFS, median (95% CI), months 2.3 (1.9-3.6) OS, median (95

Sigfox and Cube Infrastructure Managers Announce Major Partnership in IoT Infrastructure18.9.2020 10:30:00 EESTPress release

Sigfox, the global 0G network1 and cloud provider for industrial data, is proud to announce a new strategic alliance with Cube Infrastructure Managers (Cube), through the sale of its German 0G network to Cube. Sigfox has grown its 0G IoT services by rolling out 0G networks across 72 countries and regions, which was largely achieved with partners called Sigfox Operators. These operators are the owners of the 0G networks, which they operate as exclusive connectivity providers of Sigfox IoT services, offering worldwide connectivity to customers. The sale of the German network to Cube will allow Sigfox to finance its continued innovation efforts in data value extraction and improvements in cloud algorithms to reduce energy consumption and allow the implementation of even more cost-effective devices and sensors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200918005116/en/ Cube Infrastructure Managers, the European infrastructu

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom